Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | NAAA | Q02083 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9615745 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL25752209 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL17003978 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL6269938 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL10745323 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL8671910 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL8587006 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL10868669 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL6890835 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL3420576 | 0.98 | KMT2A (0.56) | KMT2AMEN1FAAHNAAAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0976796-B1 | Cyclic urea surfactants | AIR PROD & CHEM (US) | 2004-09-22 | — | — | EP | claimed |
| US-6262156-B1 | FOR WATER-BASED COMPOSITIONS, PARTICULARLY COATING, INK, AND AGRICULTURAL COMPOSITIONS, MANIFESTING REDUCED EQUILIBRIUM AND DYNAMIC SURFACE TENSION BY INCORPORATION OF A SURFACE TENSION REDUCING CERTAIN CYCLIC UREA COMPOUNDS | AIR PRODUCTS AND CHEMICALS, INC. | 2001-07-17 | — | — | US | claimed |
| US-6238849-B1 | CLEANING COMPOSITIONS MANIFESTING REDUCED EQUILIBRIUM AND DYNAMIC SURFACE TENSION | AIR PRODUCTS AND CHEMICALS, INC. | 2001-05-29 | — | — | US | claimed |
| EP-0976796-A2 | Cyclic urea surfactants | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2000-02-02 | — | — | EP | claimed |
| US-5972431-A | Cyclic urea surfactants | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1999-10-26 | — | — | US | claimed |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210002433-A1 | BIOCOMPATIBLE HYDROGEL CAPSULES AND PROCESS FOR PREPARING SAME | SIGILON THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| EP-0976796-B1 | Cyclic urea surfactants | AIR PROD & CHEM (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6262156-B1 | FOR WATER-BASED COMPOSITIONS, PARTICULARLY COATING, INK, AND AGRICULTURAL COMPOSITIONS, MANIFESTING REDUCED EQUILIBRIUM AND DYNAMIC SURFACE TENSION BY INCORPORATION OF A SURFACE TENSION REDUCING CERTAIN CYCLIC UREA COMPOUNDS | AIR PRODUCTS AND CHEMICALS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-6238849-B1 | CLEANING COMPOSITIONS MANIFESTING REDUCED EQUILIBRIUM AND DYNAMIC SURFACE TENSION | AIR PRODUCTS AND CHEMICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| US-6179906-B1 | REDUCING SURFACE TENSION | AIR PRODUCTS AND CHEMICALS, INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0976796-A2 | Cyclic urea surfactants | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5972431-A | Cyclic urea surfactants | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002433-A1 | BIOCOMPATIBLE HYDROGEL CAPSULES AND PROCESS FOR PREPARING SAME | ACMSD, ALG1, COL2A1 | KMT2A 4101/4885MEN1 3085/4885FAAH 3246/4885 |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | MSI2, CXCL12, SOST | KMT2A 2980/4885MEN1 81/4885FAAH 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.